KR101518014B1 - 부인과 질환의 치료에서의 락트산 올리고머의 용도 - Google Patents

부인과 질환의 치료에서의 락트산 올리고머의 용도 Download PDF

Info

Publication number
KR101518014B1
KR101518014B1 KR1020097022696A KR20097022696A KR101518014B1 KR 101518014 B1 KR101518014 B1 KR 101518014B1 KR 1020097022696 A KR1020097022696 A KR 1020097022696A KR 20097022696 A KR20097022696 A KR 20097022696A KR 101518014 B1 KR101518014 B1 KR 101518014B1
Authority
KR
South Korea
Prior art keywords
lactic acid
vaginal
composition
oligomer
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097022696A
Other languages
English (en)
Korean (ko)
Other versions
KR20100016060A (ko
Inventor
그렉 바첼러
토마스 헤드네
요르겐 존슨
버너 슈베르트
크리스터 스로그젠
올로브 스터너
말고자트 스니토스카
Original Assignee
라큐어 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 라큐어 에이비 filed Critical 라큐어 에이비
Publication of KR20100016060A publication Critical patent/KR20100016060A/ko
Application granted granted Critical
Publication of KR101518014B1 publication Critical patent/KR101518014B1/ko
Assigned to 콤베 인코퍼레이티드, 콤베 인터내셔날, 엘엘씨 reassignment 콤베 인코퍼레이티드 권리의 전부이전등록 Assignors: 라큐어 에이비
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020097022696A 2007-03-30 2008-03-28 부인과 질환의 치료에서의 락트산 올리고머의 용도 Expired - Fee Related KR101518014B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200700508 2007-03-30
DKPA200700508 2007-03-30
PCT/EP2008/002505 WO2008119518A1 (en) 2007-03-30 2008-03-28 Use of oligomers of lactic acid in the treatment of gynaecological disorders

Publications (2)

Publication Number Publication Date
KR20100016060A KR20100016060A (ko) 2010-02-12
KR101518014B1 true KR101518014B1 (ko) 2015-05-06

Family

ID=39494560

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097022696A Expired - Fee Related KR101518014B1 (ko) 2007-03-30 2008-03-28 부인과 질환의 치료에서의 락트산 올리고머의 용도

Country Status (19)

Country Link
US (3) US8425894B2 (enExample)
EP (2) EP2679222A1 (enExample)
JP (2) JP5409596B2 (enExample)
KR (1) KR101518014B1 (enExample)
CN (2) CN101677980B (enExample)
AU (1) AU2008234064B2 (enExample)
BR (1) BRPI0809330B8 (enExample)
CA (1) CA2681803C (enExample)
CY (1) CY1115310T1 (enExample)
DK (1) DK2142186T3 (enExample)
ES (1) ES2482190T3 (enExample)
HR (1) HRP20140559T1 (enExample)
MX (1) MX2009010445A (enExample)
PL (1) PL2142186T3 (enExample)
PT (1) PT2142186E (enExample)
RU (1) RU2459620C2 (enExample)
SI (1) SI2142186T1 (enExample)
WO (1) WO2008119518A1 (enExample)
ZA (1) ZA200907215B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809330B8 (pt) 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
CN101797269B (zh) * 2010-03-23 2012-01-04 杨霞 一种调节女性阴道微生态的生理平衡液
RU2422147C1 (ru) * 2010-03-29 2011-06-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ лечения неспецифического аэробного вагинита
WO2012158779A1 (en) 2011-05-17 2012-11-22 Reprotect, Inc. Reusable intravaginal delivery device, system, and method
CN102274333A (zh) * 2011-08-22 2011-12-14 谢英华 一种治疗阴道炎的外洗中药
CN102579829B (zh) * 2012-03-06 2013-09-18 康莉 一种治疗牛放线菌病的中药组合物及其制备方法
JP6352907B2 (ja) 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド 避妊殺菌剤の効果を増強するための組成物および方法
JP6149109B2 (ja) * 2012-07-16 2017-06-14 ラキュアー エービーＬａｃｃｕｒｅ Ａｂ 乳酸オリゴマー含有医薬組成物
CN102885850B (zh) * 2012-10-15 2013-08-07 山东省医疗器械研究所 一种治疗阴道炎的多孔凝胶颗粒剂
RU2691950C1 (ru) 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
US9895311B2 (en) * 2014-09-25 2018-02-20 Pharmiva Ab Foam-forming compositions and methods for delivering an active to a body cavity
MX382396B (es) 2016-04-06 2025-03-13 Gedea Biotech Ab Glucono delta-lactona para el tratamiento de infecciones fúngicas vaginales.
US10249017B2 (en) * 2016-08-11 2019-04-02 Intel Corporation Apparatus and method for shared resource partitioning through credit management
US20190209502A1 (en) * 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
EP3522879A4 (en) 2016-10-04 2020-06-03 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
CA3040422A1 (en) * 2016-10-13 2018-04-19 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
PL3773501T3 (pl) * 2018-03-29 2024-03-11 The Materia Company Limited Preparat dopochwowy
CN113423470B (zh) * 2019-02-13 2024-07-09 三吉油脂株式会社 化妆品配合剂、化妆品及其制造方法
EP4240321A1 (en) * 2020-11-09 2023-09-13 Peptonic Medical AB Composition for treating and/or preventing fungal infections
US20250161348A1 (en) 2022-03-01 2025-05-22 Combe Incorporated Process for preparation of compositions of oligomers of lactic acid
EP4590289A4 (en) * 2023-07-07 2025-11-26 Changchun Sinobiomaterials Co Ltd MUSCLE ATROPHY

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006001766A1 (en) * 2004-06-23 2006-01-05 Nestor Medical Ab Composition comprising lactic acid and lactoferrin

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4431427A (en) * 1981-10-05 1984-02-14 University Of Delaware Tampons and their manufacture
US5274127A (en) * 1990-09-18 1993-12-28 Biopak Technology, Ltd. Lactide production from dehydration of aqueous lactic acid feed
JP2919912B2 (ja) 1990-05-23 1999-07-19 鐘紡株式会社 修飾プロテアーゼ及びその製造法
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
JPH07132127A (ja) 1993-06-17 1995-05-23 Mitsui Toatsu Chem Inc 生理用ナプキン
JPH07258526A (ja) 1994-02-24 1995-10-09 Ecological Chem Prod Co 水分含有食品を包装するための組成物及び方法
US5521278A (en) * 1994-08-18 1996-05-28 Ecological Chemical Products Integrated process for the manufacture of lactide
JP2864218B2 (ja) 1994-12-06 1999-03-03 株式会社日本製鋼所 ポリ乳酸共重合体の製造方法
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
JPH09227388A (ja) * 1996-02-15 1997-09-02 Naganushi Tetsuaki 大腸癌、食道癌及び乳癌より選ばれた癌に用いる抗悪性腫瘍剤
WO1997045066A1 (en) 1996-05-31 1997-12-04 Uromed Corporation Urinary medical devices
US6229046B1 (en) 1997-10-14 2001-05-08 Cargill, Incorported Lactic acid processing methods arrangements and products
JP2000072680A (ja) * 1998-08-25 2000-03-07 Shiyumeidou:Kk 免疫機能調節剤
JP2001139476A (ja) * 1999-11-15 2001-05-22 Youichirou Naganushi 癌を含めた悪性新生物に用いる抗悪性腫瘍剤
RU2163810C1 (ru) * 2000-05-18 2001-03-10 Майорова Нина Федоровна Состав для удаления доброкачественных новообразований на коже и слизистых и способ его получения
EP1358884A1 (en) 2001-01-12 2003-11-05 Amato Pharmaceutical Products, Ltd. Preventives for microbial infections
EP1362594A1 (en) 2001-01-24 2003-11-19 Amato Pharmaceutical Products, Ltd. Anti-stress agents
US20020177624A1 (en) * 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
JP2002275256A (ja) * 2001-03-19 2002-09-25 Tendou Seiyaku Kk 乳酸オリゴマーの製造方法
AU2002325614A1 (en) * 2001-08-16 2003-03-03 Pharmacon-Forschung Und Beratung Gmbh Compounds containing lactic acid elements, method for the production and use thereof as pharmaceutically active substances
TW200300080A (en) 2001-11-06 2003-05-16 Education Instr Co Ltd Antitumor agent containing lactic acid oligomer mixture
JP2004307561A (ja) 2003-04-02 2004-11-04 Tendou Seiyaku Kk 環状乳酸オリゴマーの製造方法
SI1617834T1 (sl) 2003-05-01 2007-02-28 Innogene Kalbiotech Pte Ltd Uporaba farmacevtskega sestavka, ki vsebuje mlecno kislino ali laktat in kalij, za zdravljenje mozganskega edema in mozganske poskodbe
JP4316299B2 (ja) 2003-06-03 2009-08-19 学校法人東海大学 鎖状乳酸オリゴマー誘導体およびその製造方法
JP2005126361A (ja) * 2003-10-23 2005-05-19 Tendou Seiyaku Kk ポリ乳酸混合物を含むマトリックスメタロプロテアーゼ抑制剤
CN1562049A (zh) * 2004-04-02 2005-01-12 聂四平 低聚果糖在制备治疗及预防阴道炎药中的应用
US20050271726A1 (en) * 2004-06-02 2005-12-08 Albert Crum Immune enhancing compositions and methods of use thereof
JP2006232909A (ja) 2005-02-23 2006-09-07 Tokai Univ 環状オリゴ乳酸
JP4431102B2 (ja) 2005-11-11 2010-03-10 キャタピラージャパン株式会社 カウンタウエイト及びカウンタウエイトの製造方法並びに作業機械
RU2308970C1 (ru) * 2006-03-10 2007-10-27 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Антибактериальное средство для лечения внутриклеточных инфекций
JP2007258526A (ja) 2006-03-24 2007-10-04 Konica Minolta Holdings Inc 有機エレクトロルミネッセンス素子、及び有機エレクトロルミネッセンスディスプレイ
JP2008157576A (ja) 2006-12-26 2008-07-10 Sharp Corp 加湿機
BRPI0809330B8 (pt) 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006001766A1 (en) * 2004-06-23 2006-01-05 Nestor Medical Ab Composition comprising lactic acid and lactoferrin

Also Published As

Publication number Publication date
PL2142186T3 (pl) 2014-09-30
RU2459620C2 (ru) 2012-08-27
CN101677980A (zh) 2010-03-24
US9315444B2 (en) 2016-04-19
ZA200907215B (en) 2014-03-26
PT2142186E (pt) 2014-07-17
JP5409596B2 (ja) 2014-02-05
AU2008234064A1 (en) 2008-10-09
CY1115310T1 (el) 2017-01-04
EP2142186B1 (en) 2014-04-30
EP2142186A1 (en) 2010-01-13
KR20100016060A (ko) 2010-02-12
EP2679222A1 (en) 2014-01-01
CN101677980B (zh) 2013-10-23
BRPI0809330B1 (pt) 2019-12-17
JP2014012675A (ja) 2014-01-23
CN103830216A (zh) 2014-06-04
ES2482190T3 (es) 2014-08-01
CA2681803C (en) 2014-08-05
WO2008119518A1 (en) 2008-10-09
US8912232B2 (en) 2014-12-16
HRP20140559T1 (hr) 2014-08-01
MX2009010445A (es) 2010-01-29
CN103830216B (zh) 2016-08-17
US20130317104A1 (en) 2013-11-28
BRPI0809330B8 (pt) 2021-05-25
US8425894B2 (en) 2013-04-23
US20150025142A1 (en) 2015-01-22
JP5793542B2 (ja) 2015-10-14
US20110020265A1 (en) 2011-01-27
DK2142186T3 (da) 2014-08-04
SI2142186T1 (sl) 2014-08-29
CA2681803A1 (en) 2008-10-09
JP2010523480A (ja) 2010-07-15
BRPI0809330A2 (pt) 2014-09-09
RU2009140141A (ru) 2011-05-10
AU2008234064B2 (en) 2013-02-07

Similar Documents

Publication Publication Date Title
CN103830216B (zh) 乳酸低聚物在制备用于治疗妇科病的药物中的应用
CN101327201B (zh) 棉酚或其类似物的液体制剂及其制备方法和用途
CN104470498B (zh) 含有低聚乳酸的药物组合物
HK1192840A (en) Use of oligomers of lactic acid in the treatment of gynaecological infections
KR20140054067A (ko) 인간 유두종 바이러스를 치료하기 위한 조성물 및 방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20180406

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20190416

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250430

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250430

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250430